Header Logo

Connection

Priyabrata Mukherjee to Ovarian Neoplasms

Back to Details
This is a "connection" page, showing publications Priyabrata Mukherjee has written about Ovarian Neoplasms.
Priyabrata Mukherjee
Connection Strength
4.681
Ovarian Neoplasms
  1. MicroRNA-195 controls MICU1 expression and tumor growth in ovarian cancer. EMBO Rep. 2020 10 05; 21(10):e48483.
    View in: PubMed
    Score: 0.441
  2. Switching the intracellular pathway and enhancing the therapeutic efficacy of small interfering RNA by auroliposome. Sci Adv. 2020 07; 6(30):eaba5379.
    View in: PubMed
    Score: 0.438
  3. Gold Nanoparticles Disrupt Tumor Microenvironment - Endothelial Cell Cross Talk To Inhibit Angiogenic Phenotypes in Vitro. Bioconjug Chem. 2019 06 19; 30(6):1724-1733.
    View in: PubMed
    Score: 0.404
  4. Cystathionine ß-synthase regulates mitochondrial morphogenesis in ovarian cancer. FASEB J. 2018 08; 32(8):4145-4157.
    View in: PubMed
    Score: 0.371
  5. MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634.
    View in: PubMed
    Score: 0.352
  6. Role of cystathionine beta synthase in lipid metabolism in ovarian cancer. Oncotarget. 2015 Nov 10; 6(35):37367-84.
    View in: PubMed
    Score: 0.317
  7. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget. 2014 Aug 15; 5(15):6453-65.
    View in: PubMed
    Score: 0.291
  8. Understanding protein-nanoparticle interaction: a new gateway to disease therapeutics. Bioconjug Chem. 2014 Jun 18; 25(6):1078-90.
    View in: PubMed
    Score: 0.286
  9. Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance. PLoS One. 2013; 8(11):e79167.
    View in: PubMed
    Score: 0.276
  10. Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proc Natl Acad Sci U S A. 2013 Apr 23; 110(17):6700-5.
    View in: PubMed
    Score: 0.265
  11. Identifying new therapeutic targets via modulation of protein corona formation by engineered nanoparticles. PLoS One. 2012; 7(3):e33650.
    View in: PubMed
    Score: 0.246
  12. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009 Dec 01; 69(23):9090-5.
    View in: PubMed
    Score: 0.209
  13. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7659-66.
    View in: PubMed
    Score: 0.196
  14. KRCC1: A potential therapeutic target in ovarian cancer. FASEB J. 2020 02; 34(2):2287-2300.
    View in: PubMed
    Score: 0.105
  15. LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res. 2018 04 15; 78(8):1923-1934.
    View in: PubMed
    Score: 0.092
  16. Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer. Oncotarget. 2016 Nov 08; 7(45):72845-72859.
    View in: PubMed
    Score: 0.085
  17. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104.
    View in: PubMed
    Score: 0.081
  18. Hepatoma derived growth factor (HDGF) dynamics in ovarian cancer cells. Apoptosis. 2016 Mar; 21(3):329-39.
    View in: PubMed
    Score: 0.081
  19. Probing novel roles of the mitochondrial uniporter in ovarian cancer cells using nanoparticles. J Biol Chem. 2013 Jun 14; 288(24):17610-8.
    View in: PubMed
    Score: 0.066
  20. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One. 2011 Mar 21; 6(3):e17918.
    View in: PubMed
    Score: 0.057
  21. BMI1, a new target of CK2a. Mol Cancer. 2017 03 07; 16(1):56.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.